About  |  Employment  |  Media Center  |  Staff  |  Events  |  Contacts  |  Espańol  |  Français اللغة العربية 

      Search the Council's Web site:

ABSTRACT

Teleshova, Natalia, Jessica Kenney, Jennifer Jones, Jason Marshall, Gary Van Nest, Jason Dufour, Rudolf Bohm, Jeffrey D. Lifson, Agegnehu Gettie, and Melissa Pope. 2004. “CpG-C ISS-ODN activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-γ-secreting SIV-specific T cells,” Journal of Immunology 173(3): 1647–1657. (offsite link)

There are two principle subsets of dendritic cells (DCs); CD11c+CD123 myeloid DCs (MDCs) and CD11cCD123+ plasmacytoid DCs (PDCs). DC activation via TNF-TNFRs (e.g., CD40L) and TLRs (e.g., immunostimulatory oligodeoxyribonucleotides (ISS-ODNs)) is crucial for maximal stimulation of innate and adaptive immunity. Macaque DC biology is being studied to improve HIV vaccines using the SIV macaque model. Using lineage (Lin) markers to exclude non-DCs, LinHLA-DR+CD11c+CD123 MDCs and LinHLA-DR+CD11cCD123+ PDCs were identified in the blood of uninfected macaques and healthy macaques infected with SIV or simian-human immunodeficiency virus. Overnight culture of DC-enriched Lin-depleted cells increased CD80 and CD86 expression. IL-12 production and CD80/CD86 expression by MDC/PDC mixtures was further enhanced by CD40L and ISS-ODN treatment. A CpG-B ISS-ODN increased CD80/CD86 expression by PDCs, but resulted in little IFN-α secretion unless IL-3 was added. In contrast, a CpG-C ISS-ODN and aldrithiol-2-inactivated (AT-2) SIV induced considerable PDC activation and IFN-α release without needing exogenous IL-3. The CpG-C ISS-ODN also stimulated IL-12 release (unlike AT-2 SIV) and augmented DC immunostimulatory activity, increasing SIV-specific T cell IFN-γ production induced by AT-2 SIV-presenting MDC/PDC-enriched mixtures. These data highlight the functional capacities of MDCs and PDCs in naive as well as healthy, infected macaques, revealing a promising CpG-C ISS-ODN-driven DC activation strategy that boosts immune function to augment preventative and therapeutic vaccine efficacy.

Return to Mucosal Innate and Adaptive Immunity and HIV project page



Print this page

@
E-mail this page

This page updated
31 August 2005